



IFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1554-F)

In the Application of:)	
)	
Varnum et al.)	Before the Examiner:
)	
Serial No.)	
10/656,769)	Group Art Unit: 1644
)	
Filed:)	
September 5, 2003)	
)	
For:)	Confirmation No.: 8860
Therapeutic Human Anti-IL-1R1)	
Monoclonal Antibody)	

Mail Stop Amendment
Commissioner for Patents
Alexandria, VA 22313-1450


TRANSMITTAL LETTER

Sir:

In regard to the above-identified application:

1. We are transmitting herewith the attached
 - a. Response to Restriction Requirement; and
 - b. Return Receipt Postcard
2. With respect to additional fees:
 - a. No fees are required.
3. Please charge any deficiency in the amount due, or credit any overpayment, to Deposit Account No. **13-2490**. A duplicate copy of this sheet is enclosed.
4. **CERTIFICATE OF MAILING UNDER 37 CFR § 1.8:** The undersigned hereby certifies that this Transmittal Letter and the papers, as described in paragraph 1 herein-above, are being deposited with the United States Postal Service with sufficient postage as "First Class Mail" in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this **28th** day of **July, 2005**.

By:


Jason J. Derry
Reg. No. 50,692



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1554-F)

In the Application of:)	
)	
Varnum et al.)	Before the Examiner:
)	
Serial No. 10/656,769)	
)	Group Art Unit: 1640
Filed: September 5, 2003)	
)	
For: Therapeutic Human Anti-IL-1R1)	Confirmation No.: 8860
Monoclonal Antibody)	

Mail Stop Amendment
Commissioner for Patents
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

Responsive to the Restriction Requirement mailed June 29, 2005, Applicants elect group III (claims 5(c), 10, 11, 32-38, 40, and 55-59, drawn to antibodies that bind IL-1R1 wherein the heavy chain variable region is SEQ ID NO: 16 and the light chain variable region is SEQ ID NO: 18) with traverse.

Applicants note that the antibodies recited in claims 46-54 comprising SEQ ID NO: 63 (heavy chain CDR1), SEQ ID NO: 66 (heavy chain CDR2), SEQ ID NO: 69 (heavy chain CDR3), SEQ ID NO: 71 (light chain CDR1), SEQ ID NO: 73 (light chain CDR2), and SEQ ID NO: 75 (light chain CDR3) are related to the antibodies recited in elected group III. Applicants note that these antibodies in claims 46-54 will be examined along with group III as stated at the bottom of page 6 of the Restriction Requirement.

In addition, Applicants acknowledge that linking claims 1, 2, 42, and 44 will be examined with group III, as stated on page 7 of the Restriction Requirement. Applicants also understand that the restriction requirement as to the linked inventions will be withdrawn upon allowance of these linking claims, and claims that depend from or otherwise include all the limitations of allowable linking claims will be entitled to examination in the instant application.

Applicants also note that withdrawn process claims that depend from or include all the


limitations of an allowable product claim will be rejoined pursuant to MPEP §821.04.

The Examiner in charge of this application is invited to contact the undersigned representative as indicated below if it is believed to be helpful.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff LLP

Date: July 28, 2005

By:


Jason J. Derry
Reg. No. 50,692

Phone: 312-913-0001

Fax: 312-913-0002